Comparison of the Anti-Tumour Activity of the Somatostatin Receptor (SST) Antagonist [<sup>177</sup>Lu]Lu-Satoreotide Tetraxetan and the Agonist [<sup>177</sup>Lu]Lu-DOTA-TATE in Mice Bearing AR42J SST<sub>2</sub>-Positive Tumours

Comparison of the Anti-Tumour Activity of the Somatostatin Receptor (SST) Antagonist [<sup>177</sup>Lu]Lu-Satoreotide Tetraxetan and the Agonist [<sup>177</sup>Lu]Lu-DOTA-TATE in Mice Bearing AR42J SST<sub>2</sub>-Positive Tumours

Limited experiments have compared the treatment effects of repetitive cycles of radiolabelled somatostatin (SST) analogues. In vitro and in vivo experiments were conducted in an AR42J cancer cell model, comparing the antagonist [<sup>177</sup>Lu]Lu-satoreotide tetraxetan with the agonist...

Full description

Bibliographic Details
Main Authors: Pascale Plas, Lorenzo Limana, Denis Carré, Amath Thiongane, Olivier Raguin, Rosalba Mansi, Florence Meyer-Losic, Stéphane Lezmi
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:Pharmaceuticals
Subjects:
[<sup>177</sup>Lu]Lu-satoreotide tetraxetan
[<sup>177</sup>Lu]Lu-DOTA-TATE
somatostatin receptor subtype 2
AR42J
peptide receptor radionuclide therapy
Online Access:https://www.mdpi.com/1424-8247/15/9/1085

Internet

https://www.mdpi.com/1424-8247/15/9/1085

Similar Items